← Leaderboards
Moriya Tsuji
New York University School Of Medicine
$11,242,468
Attributed
$11,242,468
Total exposure
11
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.4M · FY2005–24$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$11,242,468 · 11
By mechanism
R01$5,412,230 · 3
N01$2,501,040 · 1
R21$1,500,549 · 3
R56$1,394,959 · 2
R29$224,710 · 1
K02$208,980 · 1
Top collaborators
No co-investigators on record.
Most similar at New York University School Of Medicine
Same institution · by research overlap
- Photini Sinnis$7,914,418
- Elizabeth H Nardin$7,927,613
- Victor Nussenzweig$5,382,044
- Ana Rodriguez$8,975,691
- Benjamin G. Neel$33,134,772
Others in their field
Top investigators on “Malaria Vaccines”
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$227,738,417
- Lawrence Corey · Fred Hutchinson Cancer Center$227,738,417
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$82,291,297
- Stephen Lev Hoffman · Sanaria, Inc.$78,840,590
- Constance Ann Benson · University Of California, San Diego$65,790,143
- David Heimbrook · Leidos Biomedical Research, Inc.$61,561,099
Research focus
Malaria VaccinesMalariaVaccinesImmunityBaseT-LymphocyteIn VivoAntigensMediatingAdenovirusesCd8b1 GeneCellsLeadImmunizationAntimalarialsParasitesAntibodiesCircumsporozoite ProteinResponseChildIn VitroImmunogenicityT Cell ResponseRecombinants
Grant awards (27)
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES$1,089,350
N01 · FY2024 · AI · contact PI
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES$1,411,690
N01 · FY2023 · AI · contact PI
Group 1 CD1-restricted human T cells induced by a whole sporozoite-based malaria vaccine$162,000
R21 · FY2021 · AI · contact PI
Group 1 CD1-restricted human T cells induced by a whole sporozoite-based malaria vaccine$283,500
R21 · FY2020 · AI · contact PI
Mechanisms of induction of protective anti-malarial CD8+ T Cells$350,000
R01 · FY2017 · AI · contact PI
CD1d/NKT-binding glycolipids in enhancing the immunogenicity of a malaria vaccine$448,750
R01 · FY2016 · AI · contact PI
Mechanisms of induction of protective anti-malarial CD8+ T Cells$350,000
R01 · FY2016 · AI · contact PI
CD1d/NKT-binding glycolipids in enhancing the immunogenicity of a malaria vaccine$448,750
R01 · FY2015 · AI · contact PI
Mechanisms of induction of protective anti-malarial CD8+ T Cells$350,000
R01 · FY2015 · AI · contact PI
CD1d/NKT-binding glycolipids in enhancing the immunogenicity of a malaria vaccine$448,750
R01 · FY2014 · AI · contact PI
Mechanisms of induction of protective anti-malarial CD8+ T Cells$350,000
R01 · FY2014 · AI · contact PI
CD1d/NKT-binding glycolipids in enhancing the immunogenicity of a malaria vaccine$421,825
R01 · FY2013 · AI · contact PI
Optimizing adenoviral vector to elicit a potent anti-malaria immunity$447,171
R01 · FY2012 · AI · contact PI
CD1d/NKT-binding glycolipids in enhancing the immunogenicity of a malaria vaccine$441,875
R01 · FY2012 · AI · contact PI
Optimizing adenoviral vector to elicit a potent anti-malaria immunity$447,171
R01 · FY2011 · AI · contact PI
Optimizing adenoviral vector to elicit a potent anti-malaria immunity$451,688
R01 · FY2010 · AI · contact PI
CD1d/NKT-binding Glycolipids as an Adjuvant for a T cell-based Malaria Vaccine$456,250
R56 · FY2009 · AI · contact PI
Optimizing adenoviral vector to elicit a potent anti-malaria immunity$456,250
R01 · FY2009 · AI · contact PI
CD1d/NKT-binding Glycolipids as an Adjuvant for a T cell-based Malaria Vaccine$478,188
R56 · FY2008 · AI · contact PI
Improving Malaria Pre-Erythrocytic Vaccines$460,521
R56 · FY2008 · AI · contact PI
Novel Humanized Mice to Study CD1b/c-Mediated Immunity$307,598
R21 · FY2006 · AI · contact PI
Novel Humanized Mice to Study CD1b/c-Mediated Immunity$316,459
R21 · FY2005 · AI
NKT cells: Novel Protective T cells against malaria$430,992
R21 · FY2001 · AI
ADENOVIRUS--AN EFFICIENT VECTOR OF ANTIMALARIA IMMUNITY$110,344
R29 · FY2001 · AI
ENHANCEMENT OF ADENOVIRUS INDUCED ANTIMALARIA PROTECTION$104,490
K02 · FY2001 · AI
ADENOVIRUS--AN EFFICIENT VECTOR OF ANTIMALARIA IMMUNITY$114,366
R29 · FY2000 · AI
ENHANCEMENT OF ADENOVIRUS INDUCED ANTIMALARIA PROTECTION$104,490
K02 · FY2000 · AI